Market access without tears
This article was originally published in The Gray Sheet
Executive Summary
AMO vows to enter the $450 mil. artificial tears/dry eye care market in July 2005, following the expiration of a no-compete clause with former parent company Allergan. At the First Albany Capital analyst conference Dec. 7, Mazzo says AMO is ready to produce the solution using the same formulators as the firm uses for contact lens lubricants and solutions, but, failing that, "I will go out and acquire a technology"...